The results of a research collaboration between the neuroscience group of QPS Netherlands B.V. and Professor Peter Paul de Deyn and coworkers of the Department of Neurology and Alzheimer Research Center, University Medical Center Groningen, were recently published in the European Journal of Clinical Investigations (Naudé et al. 2017) entitled “Dynamics of neutrophil gelatinase-associated lipocalin …
Writing the Book on Beta-Alanine for Sports Performance: QPS MRA’s Doug Kalman Takes a Stand
Ever wish that really big hill you always cycle up would seem a little less hilly? Want to swing impressive poundage at your next kettlebell class?According to Doug Kalman PhD, RD, Director of Nutrition & Endocrinology at QPS MRA (Miami Research Associates) and other contributors to the International Society of Sports Nutrition’s position paper on …
QPS Aids Development of Cannabinoid Chewing Gum, for MS Patients
Cannabinoid bioscience has come a long way. New York-based Axim Biotech is at the forefront, developing – among many other, related products – a multi-layered, slow-release cannabinoid chewing gum. Not for the candy stand, MedChewRx® is seeking FDA and EMA approval for the treatment of pain and spasticity associated with multiple sclerosis. Characteristically, QPS is …
DMPK scientists from Exelixis and QPS publish on “Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites” in DMD
Read the original Exelexis-supported publication in Drug Metabolism & Disposition (DMD). Cabozantinib (COMETRIQ®) inhibits the activity of tyrosine kinases including MET, VEGFRs and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment. Cabozantinib is currently approved …
